Chris Tang

Gene therapy delivering glutamic acid decarboxylase (GAD) is known to have therapeutic effects in patients with Parkinson’s disease (PD). However, the precise mechanisms mediating the improvements remain unclear. Now, Niethammer et al. used brain metabolic network analysis in patients with PD and showed that after gene therapy, patients developed a treatment-specific brain metabolic network involving motor-cortical regions.

Behavioral variant frontotemporal dementia (bvFTD) is the most common clinical phenotype of frontotemporal lobar degeneration (FTLD), a leading cause of dementia in midlife [1x[1]Bang, J., Spina, S., and Miller, B.L. Frontotemporal dementia. Lancet. 2015; 386: 1672–1682Abstract | Full Text | Full Text PDF | PubMed | Scopus (98) | Google ScholarSee all References][1].

Consumers have grown accustomed to a steady stream of novel goods and services — smart televisions, contactless payments, ride-sharing from Uber and Lyft. Still, such innovations often can be a hard sell. They require buyers to give up old habits and to master new ways of doing things. Even when an innovation offers obvious benefit, getting people to try it means overcoming deep-seated psychological resistance to novelty and change. How can a company break through?